BMY vs IBRX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BMY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and IBRX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and IBRX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.

Full BMY guide

ImmunityBio (IBRX) is a clinical- and commercial-stage immunotherapy company built around Anktiva (nogapendekin alfa inbakicept), an IL-15 receptor agonist immunotherapy. Its lead approved use is in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and the company is pushing label expansions into BCG-naive bladder cancer and lung cancer while building out global commercial partnerships across roughly 33 to 34 countries. The founder and largest shareholder, Patrick Soon-Shiong, remains central to the story and its strategy.

Full IBRX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BMY drivers: New product portfolio ramp; Oncology and immunology depth.
• IBRX drivers: Anktiva revenue ramp; Label and indication expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For IBRX, iBRX carries the full risk profile of an unprofitable commercial-stage biotech.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; IBRX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and IBRX guides.

BMY. Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.

IBRX. The valuation is striking: a multi-billion-dollar market value against roughly ~$113M of trailing revenue implies a very high price-to-sales multiple and prices in significant future growth. The company is not profitable and funds ongoing losses partly through financing, so cash runway and dilution are central to the story. These figures are as of JULY 2026 and shift with each quarterly report and any capital raise.

Headline figures (approximate, early 2026): BMY shows revenue (ttm) ~$48 billion, operating margin ~20% (varies with acquisition charges), net income (ttm) volatile, pressured by large acquisition write-offs, dividend yield ~4-5%; IBRX shows revenue (fy2025) ~$113M net product revenue, revenue growth (q1 2026 yoy) ~168%, q1 2026 net product revenue ~$44M, cash and marketable securities (mar 31, 2026) ~$381M.

BMY and IBRX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and IBRX exposure against your real portfolio. It is not an investment adviser.